Trends in prescribing diabetes drugs that lower blood sugar and protect heart and kidney health in South Korea from 2015 to 2021

K.H.H. has no relevant disclosures. S.S. and E.N. are employees of Boehringer Ingelheim. D.J.K. has received grants or research support from Boehringer Ingelheim, LG Chem, and Novo Nordisk. D.J.K. is an Editorial Board member of the Journal of Diabetes Investigation and a co‐author of this article. To minimize bias, he was excluded from all editorial decision‐making related to the acceptance of this article for publication. The authors meet the criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The authors did not receive payment related to the development of the article. Boehringer‐Ingelheim was given the opportunity to review the manuscript for medical and scientific accuracy as well as intellectual property considerations. Approval of the research protocol: The study protocol was approved by the Institutional Review Board of Ajou University Hospital, Suwon, Republic of Korea (approval no. AJOUIRB‐EXP‐2022‐355). Informed consent: Because this was a retrospective study, the requirement for informed consent was waived. Approval date of registry and the registration no. of the study/trial: N/A. Animal studies: N/A.